Patents by Inventor Kou-ichi Jishage
Kou-ichi Jishage has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8067665Abstract: A non-human animal that produces human tissue factor (TF) without substantially producing non-human animal tissue factor, said animal having a genome in which cDNA encoding human TF has been inserted upstream of the translation initiation codon for the non-human animal genomic TF gene.Type: GrantFiled: August 12, 2009Date of Patent: November 29, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Kiyoshi Habu, Kou-ichi Jishage, Hideki Adachi, Naohiro Yabuta
-
Patent number: 8013208Abstract: This invention provides methods for producing antibodies, wherein the methods comprise the step of administering an immunogen comprising both a target antigen and a background antigen to transgenic animals, into which a gene coding for the background antigen has been introduced. Since immunotolerance to the background antigens have thus been induced in the transgenic animals, the animals efficiently produce antibodies to target antigens.Type: GrantFiled: May 7, 2010Date of Patent: September 6, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tatsuhiko Kodama, Kou-ichi Jishage, Nobuo Kamada, Yoshiki Yamada
-
Patent number: 7964767Abstract: Membrane proteins that are background antigens were solubilized, and transgenic animals were produced using genes encoding these soluble proteins. Antibodies against the background antigen membrane proteins comprised in the immunogens were not found in these transgenic animals, and even when genes encoding soluble proteins were used, immunotolerance against the full-length membrane proteins could be induced. Moreover, by expressing the background antigen membrane proteins as soluble proteins inside the bodies of transgenic animals, unfavorable phenotypes that appear when the full-length membrane proteins are expressed could be avoided, and such animals were made widely available as immunized animals.Type: GrantFiled: March 31, 2005Date of Patent: June 21, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tatsuhiko Kodama, Yoshiki Yamada, Nobuo Kamada, Kou-Ichi Jishage
-
Publication number: 20100329988Abstract: The present inventors found that a physiological effect of a particular DNA can be detected independently within mice into which a pool of various DNAs in various quantities has been introduced. This finding suggests that it is possible to identify a DNA having a particular physiological effect by successively fractionating a pool of various DNAs in various quantities using the particular physiological effect seen within a mammal as an index. Such a method of screening will have the advantage of saving much time and effort as required in conventional screenings such as those utilizing transgenic and knockout mice. Furthermore, the method of screening has the additional advantage of enabling the identification of a DNA having a physiological activity, for example, even when the cells producing a physiologically active substance cannot be maintained in vitro or in immunodeficient animals, or when the cells change their characteristics during passage and stop producing the physiologically active substance.Type: ApplicationFiled: August 18, 2010Publication date: December 30, 2010Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Kiyoshi Habu, Kou-ichi Jishage, Hiroshi Suzuki
-
Publication number: 20100333220Abstract: A non-human animal that produces human tissue factor (TF) without substantially producing non-human animal tissue factor, said animal having a genome in which cDNA encoding human TF has been inserted upstream of the translation initiation codon for the non-human animal genomic TF gene.Type: ApplicationFiled: August 12, 2009Publication date: December 30, 2010Inventors: Kiyoshi Habu, Kou-ichi Jishage, Hideki Adachi, Naohiro Yabuta
-
Publication number: 20100218267Abstract: This invention provides methods for producing antibodies, wherein the methods comprise the step of administering an immunogen comprising both a target antigen and a background antigen to transgenic animals, into which a gene coding for the background antigen has been introduced. Since immunotolerance to the background antigens have thus been induced in the transgenic animals, the animals efficiently produce antibodies to target antigens.Type: ApplicationFiled: May 7, 2010Publication date: August 26, 2010Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Tatsuhiko Kodama, Kou-ichi Jishage, Nobuo Kamada, Yoshiki Yamada
-
Patent number: 7750204Abstract: This invention provides methods for producing antibodies, wherein the methods comprise the step of administering an immunogen comprising both a target antigen and a background antigen to transgenic animals, into which a gene coding for the background antigen has been introduced. Since immunotolerance to the background antigens have thus been induced in the transgenic animals, the animals efficiently produce antibodies to target antigens.Type: GrantFiled: June 4, 2003Date of Patent: July 6, 2010Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tatsuhiko Kodama, Kou-Ichi Jishage, Nobuo Kamada, Yoshiki Yamada
-
Patent number: 7592502Abstract: A non-human animal that produces human tissue factor (TF) without substantially producing non-human animal tissue factor, said animal having a genome in which cDNA encoding human TF has been inserted upstream of the translation initiation codon for the non-human animal genomic TF gene.Type: GrantFiled: May 17, 2002Date of Patent: September 22, 2009Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Kiyoshi Habu, Kou-ichi Jishage, Hideki Adachi, Naohiro Yabuta
-
Publication number: 20090092995Abstract: The present inventors found that a physiological effect of a particular DNA can be detected independently within mice into which a pool of various DNAs in various quantities has been introduced. This finding suggests that it is possible to identify a DNA having a particular physiological effect by successively fractionating a pool of various DNAs in various quantities using the particular physiological effect seen within a mammal as an index. Such a method of screening will have the advantage of saving much time and effort as required in conventional screenings such as those utilizing transgenic and knockout mice. Furthermore, the method of screening has the additional advantage of enabling the identification of a DNA having a physiological activity, for example, even when the cells producing a physiologically active substance cannot be maintained in vitro or in immunodeficient animals, or when the cells change their characteristics during passage and stop producing the physiologically active substance.Type: ApplicationFiled: December 3, 2008Publication date: April 9, 2009Inventors: Kiyoshi Habu, Kou-Ichi Jishage, Hiroshi Suzuki
-
Publication number: 20080040820Abstract: Membrane proteins that are background antigens were solubilized, and transgenic animals were produced using genes encoding these soluble proteins. Antibodies against the background antigen membrane proteins comprised in the immunogens were not found in these transgenic animals, and even when genes encoding soluble proteins were used, immunotolerance against the full-length membrane proteins could be induced. Moreover, by expressing the background antigen membrane proteins as soluble proteins inside the bodies of transgenic animals, unfavorable phenotypes that appear when the full-length membrane proteins are expressed could be avoided, and such animals were made widely available as immunized animals.Type: ApplicationFiled: March 31, 2005Publication date: February 14, 2008Inventors: Tatsuhiko Kodama, Yoshiki Yamada, Nobuo Kamada, Kou-Ichi Jishage
-
Publication number: 20060174354Abstract: The present invention provides a transgenic animal expressing the full-length human hepatitis C virus (HCV) for the purpose of constructing a system for screening for a remedy for human hepatitis C. The present invention is a transgenic hepatitis C model animal, which has the full-length DNA of the hepatitis C virus incorporated therein and can express the full-length HCV gene, and a method of generating a hepatitis C model animal carrying the full-length HCV gene, which comprises introducing a vector containing the full-length DNA of hepatitis C virus into an ES cell, and causing the ES cells to undergo ontogenesis in a pseudo-parent.Type: ApplicationFiled: September 24, 2002Publication date: August 3, 2006Inventors: Michinori Kohara, Hiroshi Suzuki, Otoya Ueda, Kou-ichi Jishage, Asao Katsume
-
Patent number: 6982362Abstract: The present invention provides a knockout animal artificially modified to inhibit ?-TTP gene expression. This animal is useful as a tool for understanding mechanisms for the development of familial isolated vitamin E deficiency and other diseases induced by oxidative stress (e.g., arteriosclerosis, diabetes). It is also useful as a tool for developing a therapeutic agent for these diseases.Type: GrantFiled: August 24, 2000Date of Patent: January 3, 2006Inventors: Keizo Inoue, Hiroyuki Arai, Makoto Arita, Kou-ichi Jishage, Hiroshi Suzuki
-
Publication number: 20050222391Abstract: This invention provides methods for producing antibodies, wherein the methods comprise the step of administering an immunogen comprising both a target antigen and a background antigen to transgenic animals, into which a gene coding for the background antigen has been introduced. Since immunotolerance to the background antigens have thus been induced in the transgenic animals, the animals efficiently produce antibodies to target antigens.Type: ApplicationFiled: June 4, 2003Publication date: October 6, 2005Inventors: Tatsuhiko Kodama, Kou-Ichi Jishage, Nobuo Kamada, Yoshiki Yamada
-
Publication number: 20050044584Abstract: A mammal is provided, in which the LKB1 gene can be deleted phase-specifically and tissue-specifically. These mammals are highly useful as tools to reveal the onset mechanism for diseases caused by LKB1 gene deficiency, such as Peutz-Jeghers syndrome and cancers, as well as to develop therapeutic agents, methods, and so on for the diseases.Type: ApplicationFiled: September 10, 2004Publication date: February 24, 2005Inventors: Jun-Ichi Nezu, Asuka Ose, Kou-Ichi Jishage, Dieter Jenne
-
Publication number: 20040244063Abstract: A non-human animal that produces human tissue factor (TF) without substantially producing non-human animal tissue factor, said animal having a genome in which cDNA encoding human TF has been inserted upstream of the translation initiation codon for the non-human animal genomic TF gene.Type: ApplicationFiled: November 18, 2003Publication date: December 2, 2004Inventors: Kiyoshi Habu, Kou-ichi Jishage, Hideki Adachi, Noahiro Yabuta
-
Patent number: 6791006Abstract: A mammal is provided, in which the LKB1 gene can be deleted phase-specifically and tissue-specifically. These mammals are highly useful as tools to reveal the onset mechanism for diseases caused by LKB1 gene deficiency, such as Peutz-Jeghers syndrome and cancers, as well as to develop therapeutic agents, methods, and so on for the diseases.Type: GrantFiled: November 30, 2001Date of Patent: September 14, 2004Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Jun-Ichi Nezu, Asuka Ose, Kou-Ichi Jishage, Dieter E. Jenne
-
Publication number: 20040067509Abstract: The present inventors found that a physiological effect of a particular DNA can be detected independently within mice into which a pool of various DNAs in various quantities has been introduced. This finding suggests that it is possible to identify a DNA having a particular physiological effect by successively fractionating a pool of various DNAs in various quantities using the particular physiological effect seen within a mammal as an index. Such a method of screening will have the advantage of saving much time and effort as required in conventional screenings such as those utilizing transgenic and knockout mice. Furthermore, the method of screening has the additional advantage of enabling the identification of a DNA having a physiological activity, for example, even when the cells producing a physiologically active substance cannot be maintained in vitro or in immunodeficient animals, or when the cells change their characteristics during passage and stop producing the physiologically active substance.Type: ApplicationFiled: November 13, 2003Publication date: April 8, 2004Inventors: Kiyoshi Habu, Kou-Ichi Jishage, Hiroshi Suzuki
-
Publication number: 20030171323Abstract: A preventive or therapeutic agent for granuloma, specifically for granuloma occurring after ligation of a deferent duct, comprising an antagonist against the scavenger receptor of macrophage, such as antibody, as an active ingredient.Type: ApplicationFiled: December 16, 2002Publication date: September 11, 2003Inventors: Hiroshi Suzuki, Kou-ichi Jishage
-
Publication number: 20020166137Abstract: A mammal is provided, in which the LKB1 gene can be deleted phase-specifically and tissue-specifically. These mammals are highly useful as tools to reveal the onset mechanism for diseases caused by LKB1 gene deficiency, such as Peutz-Jeghers syndrome and cancers, as well as to develop therapeutic agents, methods, and so on for the diseases.Type: ApplicationFiled: November 30, 2001Publication date: November 7, 2002Inventors: Jun-Ichi Nezu, Asuka Ose, Kou-Ichi Jishage, Dieter E. Jenne